Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation.

Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation. Abstract Text:

W J Shea,B E Demas,H I Goldberg,D C Hohn,L D Ferrell,R K Kerlan,

During a 2-year period, cholangiography was performed on 17 patients with clinical evidence of cholestasis who were receiving hepatic intraarterial floxuridine (IA-FUDR) infusions for treatment of metastatic colorectal adenocarcinoma. The development of cholestasis was associated with persistently elevated alkaline phosphatase, but serial CT examinations of the liver showed no progression of the tumor. All patients had cholangiographic abnormalities (by endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangiography, or operative cholangiography) of the biliary ductal system similar to those in idiopathic sclerosing cholangitis. Certain features, however, appear specific to IA-FUDR-induced cholestasis. All patients studied had segmental involvement at the common hepatic duct bifurcation. The cystic duct and gallbladder were often involved, but the distal common bile duct was spared. Histologic features of periportal and periductal fibrosis were present in specimens obtained from percutaneous liver biopsy in three patients, cholecystectomy in four patients, and autopsy in two patients. When clinical signs of hepatic dysfunction occur in the absence of tumor progression, biliary sclerosis must be suspected.

Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation. Publishing Authors By Initials

WJ Shea,BE Demas,HI Goldberg,DC Hohn,LD Ferrell,RK Kerlan,

For similar investigative techniques: drug administration routes: infusions, parenteral: infusions, intra-arterial research abstracts see: investigative techniques: drug administration routes: infusions, parenteral: infusions, intra-arterial research

PUBMED ID PMID:

MEDLINE DATE:

Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: AJR. American journal of roentgenology

VOLUME: 146

Page Numbers: 717-21

Journal Abbreviation:

ISSN: 0361-803X

DAY: 15

MONTH: Apr

YEAR: 1986

Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7708173

Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation. Keywords Mesh Terms:

KEYWORDS: Infusions, Intra-Arterial

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation. Information

Substance Name: Floxuridine

Registry Number: 50-91-9

Grant and Affiliation Information for Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: AJR Am J Roentgenol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation Related Publications

• Conditioning for skiing and ski injury prevention.
• Dealing with catheters of excessive length.
• Foods, drugs and the federal law.
• Hepatic vascular anatomy on magnetic resonance imaging.
• Interventional biliary radiology.
• Management of portal venous complications after liver transplantation.
• Massive abdominal wall hemorrhage from injury to the inferior epigastric artery: a retrospective review.
• Reperfusion of pulmonary arteriovenous malformations after successful embolotherapy with vascular plugs.
• Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation.
• The Federal Food, Drug and Cosmetic Act; its achievements with respect to dental products.
• Therapeutic devices under the Federal Food, Drug and Cosmetic Act.
• Trial experiences with the oral antidiabetic agent BZ-55; its use in 13 diabetics over a six month period.